News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genmab, Inc. (GEN.CO) Announces Financial Results for the First Half of 2013 and Improves 2013 Financial Guidance


8/14/2013 10:17:39 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

August 14, 2013; Copenhagen, Denmark;

Interim Report First Half 2013

• Reported positive top line results in Phase III study of ofatumumab in previously untreated chronic lymphocytic leukemia (CLL)

• Received Breakthrough Therapy Designation for daratumumab

• First half net sales of Arzerra┬« increased 40% over prior year

• Improved operating result by DKK 93 million over H1 2012

• Improved guidance and year-end cash balance

Help employers find you! Check out all the jobs and post your resume.


Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES